Breaking

Trump tells Netanyahu to end Gaza war and stop Iran threats, source says, as US ramps up pressure on Israel
Children swept away in school bus among at least 49 killed in South Africa flooding
Israel recovers bodies of two dead hostagesfrom Gaza in military operation
Gaza Humanitarian Foundation says Hamas attack has killed multiple aid workers
Trump administration reviewing Biden-era submarine pact with Australia, UK
Plane crashes at airport in western Indian city of Ahmedabad
Is the S&P 500 Flashing a Bearish Divergence?
Is the S&P 500 Flashing a Bearish Divergence?

Home
Features
- View All On Demos
Buy Now
Search for:

Investing

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

Nuclear Fuels Commences 2025 Kaycee Uranium Project Drill Program

Crypto Market Recap: Bitcoin Price Nears All-time High, ETF Approval Odds Rise

Categories
- Business (278)
- Investing (963)
- Stocks (407)
- World (1,154)

Disclaimer: thevoiceofthoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 thevoiceofthoughts.com | All Rights Reserved

Top

Type above and press Enter to search. Press Esc to cancel.